Key facts
- GeneIII’s last known valuation is $55.5M (Jul 2023).
- It has raised $22.1M; the latest was Early Stage VC in May 2025.
- Notable investors include Huayi Capital, CITIC Investment Holdings, JIF Capital, Xinxiang Tuoxin.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for GeneIII
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneIII are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneIII
Developer and manufacturer of synthetic biotechnology created to provide customers with better products and services. The company focuses on the field of great health and beauty, its products are mainly oriented to the big health and big beauty markets, enabling its clients in the dietary supplements and functional skin care industries to meet the need of raw material demand.
- Sector
- Materials and Resources
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- geneiii.com.cn/
- Ownership
- Privately Held (backing)
GeneIII doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneIII shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneIII in its N-PORT filings yet. We sweep new filings monthly.